These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357 [TBL] [Abstract][Full Text] [Related]
10. Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase. Chen H; Zhang Y; Ye C; Feng TT; Han JG J Biomol Struct Dyn; 2014; 32(8):1231-47. PubMed ID: 23815795 [TBL] [Abstract][Full Text] [Related]
11. Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility. Burmistrov V; Morisseau C; D'yachenko V; Karlov D; Butov GM; Hammock BD Bioorg Med Chem Lett; 2020 Feb; 30(3):126908. PubMed ID: 31870649 [TBL] [Abstract][Full Text] [Related]
13. Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. Kodani SD; Bhakta S; Hwang SH; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD Bioorg Med Chem Lett; 2018 Feb; 28(4):762-768. PubMed ID: 29366648 [TBL] [Abstract][Full Text] [Related]
14. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. Rose TE; Morisseau C; Liu JY; Inceoglu B; Jones PD; Sanborn JR; Hammock BD J Med Chem; 2010 Oct; 53(19):7067-75. PubMed ID: 20812725 [TBL] [Abstract][Full Text] [Related]
16. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase. Eldrup AB; Soleymanzadeh F; Farrow NA; Kukulka A; De Lombaert S Bioorg Med Chem Lett; 2010 Jan; 20(2):571-5. PubMed ID: 19969453 [TBL] [Abstract][Full Text] [Related]
17. Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. Du F; Sun W; Morisseau C; Hammock BD; Bao X; Liu Q; Wang C; Zhang T; Yang H; Zhou J; Xiao W; Liu Z; Chen G Eur J Med Chem; 2021 Nov; 223():113678. PubMed ID: 34218083 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Liu JY; Tsai HJ; Morisseau C; Lango J; Hwang SH; Watanabe T; Kim IH; Hammock BD Biochem Pharmacol; 2015 Dec; 98(4):718-31. PubMed ID: 26494425 [TBL] [Abstract][Full Text] [Related]
19. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Kim IH; Nishi K; Tsai HJ; Bradford T; Koda Y; Watanabe T; Morisseau C; Blanchfield J; Toth I; Hammock BD Bioorg Med Chem; 2007 Jan; 15(1):312-23. PubMed ID: 17046265 [TBL] [Abstract][Full Text] [Related]